Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Abstract Introduction To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high-income countries using ranibizumab or aflibercept as initial treatments. Meth...

Descripción completa

Detalles Bibliográficos

Autores principales:	H. Mhmud, J. P. Vermeulen, O. A. M. Tigchelaar-Besling, F. D. Verbraak, D. Barthelmes, M. Gillies, T. L. Ponsioen, Caroline C. W. Klaver
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Adis, Springer Healthcare 2025-06-01
Colección:	Ophthalmology and Therapy
Materias:	Age-related macular degeneration Neovascular AMD Bevacizumab AMD management
Acceso en línea:	https://doi.org/10.1007/s40123-025-01178-z
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!